Efficacy and tolerability of estradiol 1mg and drospirenone 2mg in postmenopausal korean women: A double-blind, randomized, placebo-controlled, multicenter study

Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review

“…In another study, 3 mg drospirenone dose also reduced blood pressure without changing potassium levels 19. Also, in a small study blood pressure tended to decrease in the estradiol 1 mg plus drospirenone 2 mg group 18. Most of the studies agree that 2 mg drospirenone is the minimum effective dose that can achieve a blood pressure decrease 20,21…”

Dose effects of oral estradiol on bone mineral density in Japanese women with osteoporosis

“…For example, the lowest effective dose of transdermal E 2 gel delivering the equivalent of an estimated 0.0125 mg/day increased mean trough serum E 2 concentrations from 13.2 pg/ml at baseline to approximately 20 pg/ml after 12 weeks 29 , while a patch delivering an ultra-low dose of E 2 (0.014 mg/day) increased mean plasma E 2 concentrations from 4.8 pg/ml at baseline to 8.6 pg/ml after 2 years 30 . In a study in Korean postmenopausal women, 1 mg oral estradiol in combination with a progestin increased mean serum E 2 concentration from 19.9 pg/ml at baseline to 42.5 pg/ml after 16 weeks 31 .…”

Hormone Therapy for the Management of Menopausal Symptoms

“…Overall, DRSP was well tolerated with breast pain (0 participants A study conducted in 90 postmenopausal Korean women investigated the safety and tolerability of estradiol 1 mg combined with DRSP 2 mg (n ¼ 45) versus placebo (n ¼ 45) for four 28-day treatment cycles. 29 In order to be included, participants had to report at least 5 severe hot flushes for 7 of the 14 days preceding study commencement. The primary outcome evaluated was the individual relative change of hot flushes.…”

“…The study patients who received the active intervention experienced a decrease in both moderate and severe hot flushes by the first month of treatment. 29 Archer and colleagues evaluated longer term safety of DRSP on the endometrium of postmenopausal women with an intact uterus over thirteen 28-day cycles. 30 Over 1000 women with normal endometrial histology at baseline and who were not currently taking HT were randomly assigned to receive either 1 mg of estradiol alone (n ¼ 226) or 1 mg of estradiol in combination with 0.5 (n ¼ 227), 1 (n ¼ 231), 2 (n ¼ 227), or 3 mg of DRSP (n ¼ 231).…”

“…Lastly, significant increases in high-density lipoprotein cholesterol (HDL-C) were observed in the combination treatment groups as compared to the estradiol-alone group (P < .001). 29 Of note, the currently marketed combination DRSP/estradiol product in the United States contains 1 mg of estradiol and 0.5 mg of DRSP. 31 In regard to safety, statistically significantly more women experienced bleeding in all of the DRSP groups in the first 3 cycles compared to women in the estradiol-alone group (P < .001).…”